Bobby Moy and Dennis Chang Elected to Managing Director
Share:
Clarion is pleased to announce the election of Bobby Moy and Dennis Chang to managing director. Both Bobby and Dennis have been integral contributors to the firm for over 12 years, bringing deep expertise and insights to clients developing solutions for patients in the rare disease and oncology spaces. They have been instrumental to the expansion of Clarion’s client base as well as the growth and development of the firm at large.
“We are incredibly excited for Bobby to join us in navigating the future of Clarion,” says Tom Murtagh, Clarion managing director and founder. “As the senior leader in Clarion’s rare disease practice, Bobby’s experience in a broad range of therapeutic areas and projects coupled with his tireless work ethic brings extensive value to our clients and continues to build and strengthen those relationships. Additionally, he has supported internal initiatives—including the PROPEL program for advanced degree candidates—that have a direct impact on the growth of the firm, and we look forward to his continued development as a member of the senior leadership team.”
“It has been a pleasure to work alongside Dennis as he continues to deepen his knowledge in the oncology space”, shares Carol Kearney, Clarion managing director.“ He drives activities to keep Clarion on the cutting edge of cancer-related science, medicine, evolving policies, key trends, and biopharma best practices. Dennis has also raised Clarion’s profile as an oncology thought leader with articles in respected journals such as In Vivo and Cancer Advance, speaking engagements at the Emerging Frontiers in Oncology Summits and MIT Koch Institute for Integrative Cancer Research as well as co-chairing the design and execution of a workshop and speaking at the CoNNCT Initiative, which focused on accelerating novel-novel combinations for cancer. His passion for knowledge and motivation to share insights with others is inspiring for the firm, and we look forward to many more years of Dennis’ leadership.”
Bobby received an MS in Neuroscience from Harvard’s Division of Medical Sciences and received a BA with dual concentrations in History and Neuroscience from Oberlin College.
Dennis received a PhD from the Neurobiology Department at Harvard Medical School and a BScH in Life Sciences from Queen’s University in Canada.